Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. XENE
2. SPY
3. HUBS
4. NUE
5. ONON
6. AAPL
7. TRMD
8. AZN
9. NVDA
10. USO

Go back to Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
Regeneron (NASDAQ: REGN) Delayed: 785.27 -4.18 (0.53%)
Previous Close $789.45    52 Week High $592.36 
Open $787.34    52 Week Low $325.35 
Day High $794.73    P/E 206.11 
Day Low $779.65    EPS $3.81 
Volume 282,993       

BANCO SANTANDER S.A. (NYSE: SAN) Delayed: 14.33 -0.49 (3.31%)
Previous Close $14.82    52 Week High $5.58 
Open $14.42    52 Week Low $3.60 
Day High $14.46    P/E N/A 
Day Low $14.30    EPS $0.00 
Volume 2,912,493       

SANOFI (NASDAQ: SNY) Delayed: 42.51 -0.63 (1.46%)
Previous Close $43.14    52 Week High $44.76 
Open $42.75    52 Week Low $36.81 
Day High $42.77    P/E N/A 
Day Low $42.34    EPS $0.00 
Volume 891,723